











































Long-term subjective cognitive functioning following adjuvant
systemic treatment
Citation for published version:
Amidi, A, Christensen, S, Mehlsen, M, Jensen, AB, Pedersen, AD & Zachariae, R 2015, 'Long-term
subjective cognitive functioning following adjuvant systemic treatment: 7-9 years follow-up of a nationwide
cohort of women treated for primary breast cancer', British Journal of Cancer, pp. 794-801.
https://doi.org/10.1038/bjc.2015.243
Digital Object Identifier (DOI):
10.1038/bjc.2015.243
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
British Journal of Cancer
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 23. Jul. 2021
Long-term subjective cognitive functioning
following adjuvant systemic treatment: 7–9
years follow-up of a nationwide cohort of
women treated for primary breast cancer
A Amidi*,1, S Christensen1, M Mehlsen1, A B Jensen2, A D Pedersen3 and R Zachariae1
1Unit for Psychooncology and Health Psychology, Aarhus University Hospital & Aarhus University, Bartholins Allé 9, bygn. 1340,
DK-8000 Aarhus C, Denmark; 2Department of Oncology, Aarhus University Hospital, Nørrebrogade 44, DK-8000 Aarhus C,
Denmark and 3Vejlefjord Rehabilitation, Sanatorievej 27b, DK-7140 Stouby, Denmark
Background: There is growing concern among breast cancer (BC) patients and survivors about cognitive impairment following
systemic treatments. The aim of the present study was to investigate the long-term effects of standard systemic adjuvant therapies
on subjective cognitive impairment (SCI) in a large nationwide cohort of BC survivors 7–9 years after primary surgery.
Methods: Participants were recruited from the nationwide Psychosocial Factors and Breast Cancer inception cohort of Danish
women treated for primary BC. SCI was assessed with the Cognitive Failures Questionnaire and women allocated to systemic
treatment according to nationwide standard protocols were compared with women who had not received any systemic
treatments.
Results: A total of 1889 recurrence-free survivors were eligible for analysis. No difference in SCI was found between survivors
across standardized systemic treatment protocols when analyses were stratified by menopausal status and adjusted for possible
sociodemographic and treatment-related confounders. The frequency of significant SCI in a subgroup of survivors in the age
range 65–74 years was B7%.
Conclusions: No differences in long-term SCI at 7–9 years post surgery were found between women who had received systemic
therapies and those who had not. Furthermore, the observed proportion of survivors with significant SCI was comparable to
normative data. These results are important to communicate to patients, survivors, and clinicians alike, especially in the light of
increasing concern about cognitive impairment following systemic therapies.
There is growing concern among breast cancer (BC) patients and
survivors regarding possible cognitive impairment following
systemic treatments (Van Londen et al, 2014). Reports of subjective
cognitive impairment (SCI) following cancer treatment are
frequent among BC patients (Pullens et al, 2010; Ganz et al,
2013). In contrast, results from neuropsychological studies of
impairment of cognitive functions have been inconsistent (Jenkins
et al, 2006, 2008; Mehlsen et al, 2009; Yamada et al, 2010;
Koppelmans et al, 2013), and although SCI and neuropsychological
outcomes are usually poorly correlated (Pullens et al, 2010;
Hutchinson et al, 2012), understanding the course and causes of
SCI is relevant due to its potential impact on survivors’ quality of
life and daily functioning (Boykoff et al, 2009; Reid-Arndt et al,
2010; Von Ah et al, 2012). A systematic review found SCI rates in
BC populations to range from 20 to 90%, but the available evidence
regarding the association between SCI and systemic BC treatment
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was inconclusive (Pullens et al, 2010). The majority of studies
included in the review included participants ranging from 0 to 5
years in time since treatment, and most studies were based on
small samples (No100). Only little is known about the possible
long-term effects (þ 5 years) of systemic therapies on SCI in BC. A
limitation of most of the existing studies has been their primary
focus on chemotherapy (CT). Given the heterogeneity of BC
treatment with the application of different treatment protocols and
modalities, it remains unclear to what extent cognitive impair-
ments may be caused by the CT itself, or by other treatment
modalities (Pullens et al, 2010). For example, oestrogen receptor-
positive patients usually receive endocrine therapy (ET) for a
period of 5 years. Endocrine therapies suppress tumour growth by
either reducing oestrogen levels, or by blocking oestrogen sensitive
receptors (Buwalda and Schagen, 2013). Oestrogen receptors have
been located in different brain regions (McEwen and Alves, 1999)
and ET may thus have a direct effect on the brain. Studies in non-
cancer populations have observed an association between meno-
pause transitioning women and cognitive functions (Weber et al,
2013). A recent study found that over 50% of BC survivors who
were or had previously been treated with adjuvant ET were
concerned about late-effects such as cognitive dysfunction
(Van Londen et al, 2014). However, most studies investigating
SCI in survivors receiving ET have focused on the short-term
effects (Shilling and Jenkins, 2007; Ribi et al, 2012; Schilder et al,
2012; Kilickap et al, 2013; Ganz et al, 2014), and thus very
little is currently known about the possible long-term impact
of ET on SCI. Furthermore, the heterogeneity of BC treatment
remains a methodological challenge, and due to inadequate
statistical power in most studies, combined effects of adjuvant
treatments (CTþ ET) are generally poorly investigated (Buwalda
and Schagen, 2013).
The aim of the present study was to investigate the long-term
effects of standard systemic treatment protocols on SCI in a large
nationwide cohort of BC survivors 7–9 years after primary
treatment adjusted for potential confounders. We hypothesised
that survivors allocated to treatment with CT, ET, or a
combination of the two, would report higher levels of SCI
compared with women who had not received adjuvant treatment.
A secondary aim was to investigate the overall level of SCI in a
subgroup of BC survivors for whom comparable normative data
were available.
MATERIALS AND METHODS
Data sources. Participants were recruited from the nationwide
Psychosocial Factors and Breast cancer (PFAB) inception cohort of
4917 Danish women treated surgically for primary BC between
October 2001 and March 2004. The PFAB cohort was established
in collaboration with the Danish Breast Cancer Cooperative Group
(DBCG) and details concerning the cohort have previously been
published (Christensen et al, 2009). Eligible women were informed
about the study at the surgical departments, and the Charlson
Comorbidity Index (Charlson et al, 1987) was completed for each
patient.
Registry data. Addresses, Danish Civil Registration personal
identification numbers, and data concerning eligibility, comorbid-
ity, histopathology, and treatment-related variables were obtained
directly from the surgical departments responsible for treating BC
in Denmark during the inclusion period, as well as from the DBCG
registry. All departments in Denmark involved in the treatment of
BC patients systematically report information on diagnosis, treatment,
and follow-up to the DBCG database and an estimated 97% of all
eligible women having had surgery for primary BC in Denmark
during the study period were identified (Rostgaard et al, 2000).
Pre-cancer data on demographic factors, psychiatric history,
ethnicity and socioeconomic variables were obtained from the
nationwide Danish longitudinal registries through a linkage
serviced by Statistics Denmark (Thygesen et al, 2011). Data from
the different sources were linked using the women’s personal
identification numbers, a 10 digit unique number, including date of
birth, used by all public registration systems. Danish ethnicity was
defined as Danish citizenship, having been born in Denmark,
and at least one parent being a Danish citizen. Psychiatric history
was defined as previous in- or outpatient psychiatric treatment
recorded until 1-month pre-surgery. For the present study
information on disease stage at time of cohort enrolment,
subsequent recurrence and secondary cancers, and treatment
protocol assignment was updated through a linkage to the DBCG
database and the Danish Cancer Registry. The Danish Cancer
Registry includes data on the incidence of cancer in the Danish
population since 1943 (Gjerstorff, 2011).
Eligibility. Eligible patients were women between 18 and 70 years
of age at time of surgery, Danish residents, with histologically
confirmed BC T1-3, N0-3, and M0 according to the TNM
(Tumour, Node, Metastasis) classification (Singletary et al, 2002)
and no history of previous cancers, except non-melanoma skin
cancer or carcinoma in situ of the cervix uteri. Other criteria were
ability to read Danish and being capable of completing a
questionnaire. In the present study, women o35 years of age
(N= 33) at time of primary surgery were excluded because all
women in this age group are allocated to systemic therapy. Based
on updated information from DBCG and the Danish Cancer
Registry, women with secondary cancer or recurrence were also
excluded at the 7–9 year follow-up, as well as women who had not
been treated according to a DBCG standard protocol or who had
been treated according to protocols not corresponding to their
menopausal status at the time of primary surgery.
Questionnaire cohort. All eligible women were informed about
the study at the surgical departments and consecutively mailed a
questionnaire package 3–4 months post surgery. A total of 3343
women (68.0%) returned the questionnaire and constituted the
questionnaire cohort. A second assessment was conducted at a
15-month follow-up (O’Connor et al, 2011), and finally between
June and August 2011, a 7–9 year follow-up questionnaire package
was mailed out to all members of the questionnaire cohort. Two
reminders were sent after 3 and 6 weeks to those participants who
had not yet returned the questionnaire package.
Systemic treatment protocols. During the study period, the
DBCG standard protocols 2001A–E and 2004C for adjuvant
therapy were effective. The different protocols (A–E) and related
treatment details are presented in Table 1. For postmenopausal
women in protocol C, sequential treatment with Exemestan
together with Tamoxifen was introduced in DBCG protocol
2004C from June 2004. Some of the first women included from
this protocol have therefore been treated with Tamoxifen for
up to B3.5 years before the initiation of Exemestane treatment
(2.5 years).
Subjective cognitive impairment. SCI was assessed at the
7–9 year follow-up. The 25-item Cognitive Failures Questionnaire
(CFQ) assesses self-reported cognitive slips and failures in daily
activities during the past 6 months (Broadbent et al, 1982). Each
item is rated from 0 to 4 with the total score calculated as the sum
of all items ranging from 0 to 100 with higher scores indicating
higher levels of cognitive failures. The CFQ has been shown to have
good psychometric properties with evidence of criterion validity
(Broadbent et al, 1982; Bridger et al, 2013). We also calculated
scores for the three individual CFQ factors as reported by Rast et al
(2009): forgetfulness, distractibility, and false triggering. Cognitive
Failure Questionnaire normative data were obtained from a
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geriatric population (range: 64–73 years) from New Zealand
(Knight et al, 2004).
Ethical approval. The study was approved by The Regional
Science-Ethical Committees and The Danish Data Protection
Agency.
Statistical Analysis. Differences in sociodemographic and clinical
variables were tested with w2-tests for categorical variables and
univariate ANOVAs for continuous measures. CFQ total scores
were calculated for all women with an item response rate X50%
using mean substitution of missing items.
ANOVAs were conducted to assess the unadjusted associations
between the treatment protocols and CFQ total and factor scores in
the total sample. Using ANCOVA, the comparisons were repeated
with stratification by menopausal status and adjustment for
sociodemographic (age, education, ethnicity, marital status,
parental status, personal income, household wealth, occupational
status, comorbidity, and psychiatric status), and clinical (time since
surgery, type of surgery, and radiotherapy status) covariates.
Because sociodemographic factors have been found to be
associated with advanced disease progression (i.e., tumour stage)
at the time of diagnosis (Dalton et al, 2006), it is important to
adjust for these factors, as they may potentially confound the
relationship between systemic treatments and SCI. We hypo-
thesised (planned contrast) that survivors from protocol A
(no adjuvant treatment) would score lower on the CFQ compared
with survivors from protocols B–E, which included CT, ET, or
both. The stratification by menopausal status was necessary in
order to eliminate the possible confounding effect of age. This
approach was chosen because menopausal status at the time of
diagnosis (and thereby indirectly age) partly determined protocol
allocation with a higher proportion of premenopausal patients
receiving CT, and because a statistically significant negative
association was observed between age and CFQ score. In addition,
menopause may itself be related to the experience of cognitive
issues (Sullivan Mitchell and Fugate Woods, 2001). Thus for the
premenopausal group, protocol A (no adjuvant treatment) was
contrasted with protocol D (CT) and B (CTþ ET), while in the
postmenopausal group, protocol A (no adjuvant treatment) was
contrasted with protocol E (CT) and C (ET).
To test whether the overall level of SCI was higher than could be
expected, we compared the CFQ mean score from a normative
population ranging between 63 and 74 years in age with BC
survivors in the corresponding age range with a one-sample t-test.
In addition, the proportion of survivors with significant SCI was
determined as the frequency of survivors with a CFQ total scores
exceeding 1 s.d. above the mean of the normative population.
This criteria for significant SCI has been used in a previous study
(Ganz et al, 2013).
The STROBE guidelines for reporting epidemiological studies
were followed (Vandenbroucke et al, 2014). All statistical analyses
were performed using SPSS version 19.0.0.1 (IBM SPSS Inc.,
Chicago, IL, USA).
RESULTS
A total of 1889 long-term BC survivors were considered eligible for
analysis (see Figure 1). Mean substitution of missing CFQ items
were performed for 66 (3%) women. Mean overall age was 63.3
years (s.d.¼ 8.2; median¼ 64.0; range¼ 43.3–79.7 years) with an
average of 8.4 years since initial surgery (range: 7.2–9.8 years). The
majority were of Danish ethnicity (97%), had an upper secondary
education or higher (71%), were occupationally engaged (70%),
and were either married or cohabiting (78%) in the year prior to
year of primary surgery. At the time of surgery, 39.8% were pre-
menopausal. At the time of the 7–9 year follow-up, a total of
777 women (41.1%) had received CT consisting of either seven
cycles of CEF, or seven cycles of CMF. Adjuvant ET had been
administered to a total of 1234 (65.3%) women and consisted of
either 5 years of treatment with Tamoxifen (20mg) for pre-
menopausal women, or a combination of 2.5 years of treatment
with Tamoxifen (20mg) followed by 2.5 years of treatment with
Exemestane (25mg) for postmenopausal women. Demographic,
socioeconomic, and clinical variables for the pre- and postmeno-
pausal women are presented in Table 2. In the premenopausal
group, differences in demographic variables between participants
allocated to different protocols were observed for age, time since
surgery, and mean household net-wealth. No differences were
observed in the postmenopausal group (see Table 2).
Protocol allocation did not differ between eligible postmeno-
pausal participants and nonparticipants from the entire cohort
(N= 3304) at 7–9 year follow-up, but a higher proportion of
participants in the premenopausal group were allocated to protocol
D compared with nonparticipants, (w2 (2)¼ 6.4, P¼ 0.04, data not
shown). The attrition rate from 3 months to 7–9 years follow-up
was low (9.6%), and there was no statistically significant difference
between non-responders and responders at the 7–9 year follow-up
regarding treatment protocol allocation when stratified by
menopausal status (premenopausal, P¼ 0.99; postmenopausal,
P¼ 0.44, data not shown).
Cognitive Failures Questionnaire. The CFQ revealed high inter-
item consistency (Cronbach’s alpha¼ 0.92) in the current sample.
The distribution of the CFQ and other relevant covariates were
formally tested and visually inspected with P–P plots and
frequency histograms and appeared to be normally distributed.
The mean total CFQ score for the entire sample was 31.4
(s.d.¼ 12.7). A significant difference was observed between pre-
(M¼ 33.1, s.d.¼ 13.5) and postmenopausal survivors (M¼ 30.3,
s.d.¼ 12.0; t(1887)¼ 4.7, Po0.001). CFQ was negatively associated
with age (r¼  0.13, Po0.001).
Table 1. Systemic treatment protocols (A–E) grouped by menopausal status
Group Protocol Treatment Details
Premenopausal (N¼ 751) A No adjuvant treatment
B CTþET 7 cycles of CEFþ tamoxifen (20mg)a
D CT 7 cycles of CEF
Postmenopausal (N¼1138) A No adjuvant treatment
C ET Tamoxifen (20mg)þexemestane (25mg)b
E CT 7 cycles of CMF
Abbrevaitions: CEF¼ cyclophosphamide, epirubicin, and fluorouracil; CMF¼ cyclophosphamide, methotrexate, and fluorouracil; CT¼ chemotherapy; ET¼ endocrine treatment.
aDuration of 5 years.
bSequential treatment with a duration of 2.5 years of Tamoxifen followed by 2.5 years of Exemestane.
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CFQ and treatment protocols. Unadjusted and unstratified
comparisons of the treatment protocols initially revealed a
significant difference (F(11 884)¼ 5.66, Po0.001) with women
from protocols B and D (both including treatment with CEF CT)
scoring higher on CFQ total compared with women from protocol
A (no adjuvant treatment; both Po0.05). These results were
consistent for all CFQ factor scores (all Po0.01). To eliminate
potential confounding by age, subsequent planned comparisons
were stratified by menopausal status and adjusted for other
potentially confounding sociodemographic and treatment -related
variables. These analyses revealed no differences in SCI between
women allocated to protocol A, and those allocated to protocol B
or D in the premenopausal group. Similarly, in the postmenopausal
group, women allocated to protocol A did not significantly differ
from women allocated to protocol C or E. Furthermore, no
differences were found for any of the individual CFQ factor scores.
All unadjusted and adjusted analyses of CFQ total and factor scores
are presented in Table 3.
CFQ and normative data. Knight et al (2004) reported a mean
CFQ total score of 31.2 (s.d.¼ 11.2) for a healthy normative group
(N¼ 161) in the age range of 65–74 years. In the present study,
women in the corresponding age range (65–74 years, n¼ 680)
reported a CFQ mean of 29.62 (s.d.¼ 11.1), which is not
statistically different from the normative sample mean
(t(839)¼ 1.62, P¼ 0.11). Using the normative data above and the
criteria described in the Materials and Methods section, a CFQ
total score above 42.4 was considered to indicate significant SCI. In
total, 7.3% of BC survivors in the corresponding age range
exceeded this cutoff score and were accordingly classified as
experiencing significant SCI.
DISCUSSION
The primary aim of the present study was to investigate possible
long-term effects of systemic treatments on SCI in BC survivors
allocated to standard treatment protocols. We hypothesised that
women allocated to protocols that included adjuvant medical
treatments would report higher levels of SCI compared with those
who had not received adjuvant treatment. Initially, this hypothesis
was confirmed in the unstratified analyses. However, when the
necessary stratification by menopausal status due to the potential
confounding effect of age was applied, the results failed to support
the hypothesis. Hence adjuvant treatments according to standard
protocols were not found to be associated with long-term SCI.
These findings provide new insights regarding the long-term
association between systemic treatments and SCI. Although other
studies have indicated an association between systemic treatments
and SCI (Ribi et al, 2012; Deprez et al, 2014), most of these studies
have investigated this relatively shortly after treatment completion.
Our findings are consistent with another large long-term study by
Ahn et al (2007), who did not detect a difference between BC
survivors (N¼ 1933) receiving different, or combined adjuvant
treatments, an average of 4 years after treatment. Limitations of
their study, however, included considerable variability in time since
surgery, which ranged from 1 to 12 years, and the measurement of
SCI was restricted to two single items related to memory and
concentration problems. In contrast, Bender et al (2006) found that
1 year after treatment, 57 survivors who had received both CTþ
ET (N¼ 19) reported higher levels of memory complaints,
compared with those who had received surgery only (N¼ 19) or
CT (N¼ 19). Due to the small sample size, these results should be
interpreted with caution. Furthermore, between-study differences
in time since surgery limit the comparability of the studies.
Although our results did not indicate any associations between
systemic treatments and SCI, it is still important to evaluate the
overall level of SCI, as this may differ from healthy population
levels. Unfortunately, no established cutoff score is currently
available for the CFQ, so we applied normative data published for a
geriatric population (65–74 years) in New Zealand (Knight et al,
2004), which may serve as a reasonable comparison country, given
the similarities between New Zealand and Denmark in size,
educational level, and socioeconomic status (OECD Better Life
Index, 2014). The mean CFQ total score in a subgroup of the
Danish BC survivors in the corresponding age range (65–74 years)
did not statistically differ from the mean of this normative
population, suggesting that long-term BC survivors in this age
range are not experiencing pronounced cognitive issues. Further-
more, using the normative data above, we determined the
prevalence of women who reported significant SCI in this
subgroup, which amounted to 7% of all survivors between 65
and 74 years of age. The proportion of women with significant SCI
in this subgroup is lower than that observed in other studies in
Total number of patients originally included




n= 306: Secondary cancer
n= 33: Age < 35 years
n= 20: Missing data on CFQ
n= 48: Not treated according to menopausal status at study entry
n= 2: Disseminated disease at study entry
n= 1015: Did not return questionaire at 3-month follow-up
n= 219: Did not return questionnaire at 7–9 years follow-up
n= 80: Self-reported recurrence or malign secondary cancer





Alive and recurence-free at 7–9 years follow-up
Invited to 7–9 years follow-up
Participated in 7–9 years follow-up
Eligible patients available for analysis
Figure 1. Flowchart of selection of patients.
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Table 2. Sociodemographic and clinical variables by menopausal status and standard treatment protocol for systemic therapy (A–E)a
Premenopausal survivors (N¼751) Postmenopausal survivors (N¼1138)
Protocol A (CT/ET) D (CT) B (CTþET) P-valueb A (CT/ET) E (CT) C (ET) P-valueb
N (%) 139 (18.5) 104 (13.9) 508 (67.6) 247 (21.7) 165 (14.5) 726 (63.8)
Sociodemographics, mean (s.d.)
Age (years) 56.4 (4.1) 54.6 (5.3) 55.1 (4.8) 0.005 68.9 (5.0) 68.2 (4.6) 68.7 (5.0) 0.39
Time since surgery (years) 8.3 (0.68) 8.5 (0.69) 8.5 (0.68) 0.015 8.4 (0.70) 8.5 (0.64) 8.4 (0.67) 0.64
Income (in 10 000 US$)c 5.2 (3.1) 4.6 (1.7) 4.7 (2.0) 0.08 3.7 (2.0) 3.7 (2.1) 3.6 (2.0) 0.62
Mean household wealth (in 10 000 US$)c 7.2 (15.7) 3.2 (10.5) 4.6 (9.5) 0.011 8.9 (12.8) 8.0 (12.5) 9.9 (19.6) 0.42
Ethnicity, N (%) 0.33 0.18
Native 133 (95.7) 102 (98.1) 490 (96.5) 245 (99.2) 161 (97.6) 705 (97.1)
Immigrant or descendant 6 (4.3) 1 (1.0) 17 (3.3) 2 (0.8) 4 (2.4) 21 (2.9)
Education, N (%) 0.34 0.88
Graduate degree (X18 years) 12 (8.6) 11 (10.6) 31 (6.1) 7 (2.8) 7 (4.2) 24 (3.3)
oGraduate degree (14–17 years) 37 (26.6) 34 (32.7) 168 (33.1) 51 (20.6) 31 (18.8) 148 (20.4)
Upper secondary (11–13 years) 66 (47.5) 35 (33.7) 201 (39.6) 95 (38.5) 72 (43.6) 297 (40.9)
Secondary (8–10 years) 18 (12.9) 19 (18.3) 88 (17.3) 34 (13.8) 16 (9.7) 76 (10.5)
Lower secondary (7 years) 5 (3.6) 4 (3.8) 15 (3.0) 58 (23.5) 37 (22.4) 173 (23.8)
Occupational status, N (%) 0.63 0.45
Employee–medium/upper level 61 (43.9) 44 (42.3) 215 (42.3) 56 (22.7) 36 (21.8) 147 (20.2)
Employee–basic level 73 (52.5) 52 (50.0) 248 (48.8) 72 (29.1) 67(40.6) 263 (36.2)
Unemployed, recipient of benefits, etc. 4 (2.9) 4 (3.8) 28 (5.5) 70 (28.3) 36 (21.8) 192 (26.4)
Old age pension — — — 20 (8.1) 9 (5.5) 51 (7.0)
Early retirement pension 1 (0.7) 3 (2.9) 15 (3.0) 29 (11.7) 17 (10.3) 73 (10.1)
Marital status, N (%) 0.23 0.92
Married/cohabiting 108 (77.7) 89 (85.6) 398 (78.3) 191 (77.3) 129 (78.2) 557 (76.7)
Divorced/not cohabiting 31 (22.3) 15 (14.4) 110 (21.7) 56 (22.7) 36 (21.8) 169 (23.3)
Children, N (%) 0.12 0.11
No 21 (15.1) 7 (6.7) 67 (13.2) 31 (12.6) 11 (6.7) 65 (9.0)
Yes 118 (84.9) 97 (93.3) 441 (86.8) 216 (87.4) 154 (93.3) 661 (91.0)
Clinical variables
Radiotherapy, N (%) 0.002 o0.001
No 42 (30.2) 22 (21.2) 86 (16.9) 79 (32.0) 45 (27.3) 115 (15.8)
Yes 97 (69.8) 82 (78.8) 422 (83.1) 168 (68.0) 120 (72.7) 611 (84.2)
Receptor status, N (%) o0.001 o0.001
Estrogen positive 137 (98.6) — 505 (99.4) 242 (98.0) — 724 (99.7)
Estrogen negative 2 (1.4) 104 (100) — 5 (2.0) 165 (100) —
Axillary status, N (%) o0.001 o0.001
No lymph node involvement 139 (100) 53 (51.0) 196 (38.6) 247 (100) 99 (60.0) 267 (36.8)
Lymph node involvement — 51 (49.0) 312 (61.4) — 66 (40.0) 459 (63.2)
Tumour grade, N (%) o0.001 o0.001
Grade 1 87 (62.6) 1 (1.0) 109 (21.5) 159 (64.4) 6 (3.6) 160 (22.0)
Grade 2 — 18 (17.3) 241 (47.4) — 53 (32.1) 376 (51.8)
Grade 3 — 71 (68.3) 77 (15.2) — 76 (46.1) 81 (11.2)
Non-ductal tumour 49 (35.3) 12 (11.5) 76 (15.0) 82 (33.2) 29 (17.6) 109 (15.0)
Missing 3 (2.2) 2 (1.9) 5 (1.0) 6 (2.4) 1 (0.6) —
Surgery type, N (%) o0.001 o0.001
Mastectomy 42 (30.2) 51 (49.0) 282 (55.5) 84 (34.0) 91 (55.2) 398 (54.8)
Lumpectomy 97 (69.8) 53 (51.0) 226 (44.5) 163 (66.0) 74 (44.8) 328 (45.2)
Charlson comorbidity index, N (%) 0.83 0.29
No comorbidity 131 (94.2) 99 (95.2) 473 (93.1) 220 (89.1) 153 (92.7) 641 (88.3)
Comorbidity (CCI score X1) 8 (5.8) 5(4.8) 32 (6.3) 26 (10.5) 12 (7.3) 83 (11.4)
Psychiatric history, N (%)
No psychiatric history 129 (92.8) 101 (97.1) 477 (93.9) 0.34 228 (92.3) 157 (95.2) 683 (94.1) 0.46
Psychiatric history 10 (7.2) 3 (2.9) 31 (6.1) 19 (7.7) 8 (4.8) 43 (5.9)
Abbrevaitions: ANOVA¼ analysis of variance; CCI¼Charlson comorbidity index; CEF¼ cyclophosphamide, epirubicin, and fluorouracil; CMF¼ cyclophosphamide, methotrexate, and
fluorouracil; CT¼ chemotherapy; ET¼endocrine treatment; NAT¼ no adjuvant treatment.
aDanish Breast Cancer Cooperative Group (DBCG) standardized protocols: A¼NAT; B (CTþET)¼ seven cycles of CEFþ tamoxifen; C (ET)¼ tamoxifenþ exemestane; D (CT)¼ seven cycles of
CEF; E (CT)¼CMF. Missing observations p1% not shown.
bGroups were compared with univariate ANOVA for continuous variables and chi-square tests for categorical variables; all tests were two-sided.
cThe amounts were converted from Danish Kroner to US$ based on the exchange rate per 31 December 2003. A full description has been published elsewhere (Christensen et al, 2009).
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which the same criterion has been applied. For example, Ganz et al
(2013) found that 20% of BC survivors reported significant SCI
within 3 months from primary treatment. Our results may thus
indicate that SCI gradually normalises over time. However, it
should be noted that the average age of participants in that study
was generally lower, and because younger age may be associated
with more cognitive complaints, as reported in the present study,
differences in the proportion of patients with significant SCI may
be due to such age differences.
A recurrent finding regarding the relationship between objective
and subjective measures of cognitive impairment is that these are
not associated (Hermelink et al, 2010; Pullens et al, 2010;
Hutchinson et al, 2012). Although there is emerging evidence to
show that SCI in cancer patients may be related to both
neuropsychological outcomes (Ganz et al, 2013, 2014) and to
altered functional, morphological, and electrophysiological brain
properties (Deprez et al, 2011, 2014; McDonald and Saykin, 2013;
Hunter et al, 2014), SCI appears to be more strongly associated
with psychological distress, for example, symptoms of depression
and anxiety (Van Dam et al, 1998; Jenkins et al, 2006; Pullens et al,
2013). However, even if SCI was not, altogether, related to objective
impairment, it inarguably remains an equally important research
area in psychosocial cancer research, due to the well-known
association between SCI and survivors’ quality of life (Boykoff et al,
2009; Calvio et al, 2010; Wu et al, 2011; Von et al, 2013).
The present study adds to the literature in several ways. First, to
our knowledge, it is the largest study investigating the long-term
(45 years) effects of systemic therapy on SCI in BC survivors so
far. Second, the study is based on data from a nationwide cohort,
which adds considerably to the generalisability of the results. In
addition, it is the first study to investigate the association between
SCI and the allocation to standard treatment protocols for systemic
therapy. Because of the large sample size, we were able to evaluate
independent, as well as, combined effects of adjuvant treatments
administered according to standard national guidelines. Compar-
ing treatment protocols may offer a more valid approach to the
investigation of SCI with results being more generalisable and
translatable to clinical practice. As differential comparisons require
large samples with adequate statistical power to detect between-
group differences, it remains a challenge in most studies (Buwalda
and Schagen, 2013). A further strength relates to the stratification
by menopausal status in the statistical analyses. Menopausal status,
and thereby age, influences the choice of adjuvant treatment and
protocol allocation. Because age was related to SCI, this could
introduce a potential confounding effect of age. An observed effect
could thus be an age-related effect rather than an independent
effect of systemic treatment per se. Other strengths include detailed
data on relevant clinical variables as well as pre-cancer socio-
demographic variables on all eligible women utilising the unique
Danish population registries. This enabled us to adjust for multiple
potential socioeconomic confounders and to perform reliable non-
responder analysis, which did not indicate any selection bias
related to the treatment exposure (CT and/or ET).
Some limitations should also be noted. Despite the prospective
nature of the present study, the CFQ was only administered at 7–9
years follow-up, which did not allow us to explore the course of
SCI over time. Furthermore, it prevented us from exploring the
possibility of attrition bias related to the initial level of SCI. At the
3-month follow-up, responders were, on average, younger than
non-responders (See Christensen et al, 2009 for full details), which,
given the observed negative association between age and SCI, may
potentially pose a risk of an overestimation of SCI. Finally, because
CFQ normative data were not available for the whole age-span,
significant SCI was only determined for a subsample (36%) of the
cohort in the age range 63 to 74 years.
In conclusion, our results failed to confirm the hypothesis that
women treated with systemic therapy experience long-term SCI
when assessed 7–9 years post surgery. Furthermore, the observed
Table 3. Subjective Cognitive Impairment (CFQa total and factor scores) 7–9 years post surgery of women treated for primary breast
cancer, presented by menopausal status and standard treatment protocols (A–E) for systemic therapy











Fully adjustedc A vs
D/A vs B
P-value
N (%) 139 (18.5) 104 (13.9) 508 (67.6)
CFQ total score 32.4 (12.8) 34.4 (13.9) 33.0 (13.7) 0.26/0.67 0.32/0.66
Forgetfulness 13.3 (4.9) 14.2 (5.5) 13.6 (5.4) 0.17/0.50 0.19/0.51
Distractibility 10.2 (4.6) 10.6 (4.7) 10.2 (4.5) 0.55/0.95 0.60/0.89
False triggering 8.1 (4.3) 8.7 (4.7) 8.3 (4.5) 0.30/0.71 0.44/0.85











Fully adjustedc A vs
E/A vs C
P-value
N (%) 247 (21.7) 165 (14.5) 726 (63.8)
CFQ total score 30.2 (12.0) 30.9 (12.1) 30.1 (11.9) 0.55/0.93 0.75/0.72
Forgetfulness 12.8 (4.6) 12.8 (4.5) 12.9 (4.6) 0.99/0.84 0.91/0.95
Distractibility 9.1 (4.2) 9.1 (4.0) 9.0 (4.0) 0.92/0.85 0.98/0.67
False triggering 7.3 (3.8) 7.6 (3.7) 7.4 (3.9) 0.51/0.86 0.65/0.78
Abbrevaitions: CEF¼ cyclophosphamide, epirubicin, and fluorouracil; CFQ¼Cognitive Failures Questionnaire and subscales; CMF¼ cyclophosphamide, methotrexate, and fluorouracil;
CT¼ chemotherapy; ET¼ endocrine treatment.
aBroadbent et al, 1982; Rast et al, 2009.
bDanish Breast Cancer Cooperative Group (DBCG) standardized protocols: A¼no adjuvant treatment (CT, ET); B (CTþET)¼ seven cycles of CEFþ tamoxifen; C (ET)¼ tamoxifenþ
exemestane; D (CT)¼ seven cycles of CEF; E¼CMF.
cFully adjusted for age, time since treatment, education, marital status, children, mean personal income, mean household income, occupational status, comorbidity, ethnicity, psychiatric
history, surgery type, and radiotherapy.
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proportion of survivors with significant SCI in the subgroup
analysis was comparable to population norms. These results are
important to communicate to patients, survivors, and clinicians
alike, especially in the light of the increasing level of concern about
cognitive impairment following systemic therapies.
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